FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.
21 U.S.C. 352(n); 21 CFR 202.1(e)(5)-(6); FDA Quantitative Efficacy and Risk DTC Guidance (2023)
Unbranded disease-awareness pieces are outside the risk-disclosure rules only while they do not identify or suggest a specific product; brand cues, single-product category claims or a direct bridge to branded content make them promotion.
21 CFR 202.1(e), (l)(2); FDA Help-Seeking Draft Guidance (2004)
On character-limited platforms (paid search, short posts, SMS), a prescription drug benefit claim should be accompanied in the same unit by the established name, the most serious risks and a direct link to complete risk information, or the claim should not be made there.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e); FDA Character Space Draft Guidance (2014)
Data in promotion that are not in the labeling, including real-world evidence, must be consistent with the approved conditions of use and be presented with the study design, limitations and context needed to avoid misleading the reader.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(6); FDA CFL Q&A Guidance (2018)
Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.
21 CFR 202.1(e)(1); 21 U.S.C. 352(n)
Consumer-directed published and digital prescription drug product-claim ads must include a true statement of side effects, contraindications and effectiveness in brief summary form.
21 U.S.C. 352(n); 21 CFR 202.1(e)(1), (e)(3)(iii), (e)(5)-(6)
Claims that a prescription product is safer, more effective, the only or the first compared with other products require substantial evidence, normally head-to-head data, and must be accurately qualified; compounded drugs must not be marketed as FDA-approved or equivalent to a brand.
21 U.S.C. 352(a), (n), (bb); 21 CFR 202.1(e)(5), (e)(6)(ii)
Promotion may not represent or suggest that a prescription drug or biologic is more effective, more durable or useful in a broader range of conditions than substantial evidence shows.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(5)-(6)
Promotion must present risk information with prominence and readability reasonably comparable to the benefit claims and must not bury, shrink or visually minimize risks.
21 CFR 202.1(e)(5)(ii), (e)(7)(vii)-(viii); 21 U.S.C. 352(n)
Wherever the proprietary name is featured, the established (generic) name must accompany it in direct conjunction, in type at least half as large and of comparable prominence.
21 CFR 202.1(b)(1)-(3); 21 CFR 201.10(g); FDA Product Name Placement Guidance (2017)
Promotion may not represent or suggest that a prescription drug is safer or has fewer or less serious risks than shown in its labeling, including by minimizing warnings and precautions.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(5)-(7)
Prescription drug and biologic promotion may not recommend or suggest any population, dose, regimen, timing or combination that is not in the approved labeling.
21 U.S.C. 352(a), (f), (n); 21 CFR 202.1(e)(4), (e)(5), (e)(6)
Firm communications to HCPs about unapproved uses must be scientifically sound, kept separate from promotion, free of persuasive elements and accompanied by disclosures: the use is unapproved, the approved uses and labeling, study design and limitations, conflicting data and financial ties.
FDA SIUU Communications Q&A Guidance (Jan. 2025); 21 U.S.C. 352(a)
Published consumer-directed prescription drug ads must include, in conspicuous text, the statutory statement encouraging consumers to report negative side effects to FDA via MedWatch.
21 U.S.C. 352(n) (FD&C Act 502(n), FDAAA 2007 s.906)
Social content by creators, patients or HCPs who are paid by or partnered with a manufacturer or seller must clearly disclose the connection, and personal-experience claims must not imply results beyond the labeling or typical experience.
16 CFR 255.2, 255.3, 255.5; 15 U.S.C. 45; 21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(6)
Statements about what a patient will pay or save for a prescription drug ($0, free, covered, savings) must be accurate and qualified by who is eligible, the coverage involved, limits and the basis for the figure.
21 U.S.C. 352(a)(1); 15 U.S.C. 45(a)